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We investigated the formation of hydroxyl radical (OH·) and H2O2 mediated oxidation
products of a synthetic peptide, HCSAGIGRS, which is an active site sequence motif of pro-
tein tyrosine phosphatase 1B (PTP1B). We determined that a novel cysteine sulfinamide
HC[S(O)N]SAGIGRS is produced in the oxidation reaction by Fenton reagents (Fe2/H2O2) as
well as by H2O2. These products were characterized by tandem mass spectrometry experi-
ments on both singly and doubly charged precursor ions. MS3 experiments using an ion trap
instrument as well as LC-MS/MS experiments using a quadrupole time-of-flight (Q-TOF)
instrument demonstrated that HC[S(O)N]SAGIGRS is not a water loss product of cysteine
sulfinic acid [HC(SO2H)SAGIGRS]. We also obtained data from tandem mass spectrome-
try experiments that provided evidence for the existence of stable cysteine sulfenic acid
[HC(SOH)SAGIGRS] in solution. A mechanism for the formation of the cysteine sulfinamide
product is proposed based on the above experimental results. The preparation and identifi-
cation of cysteine sulfinamide in this study may provide insight into the mechanism of both
OH· and H2O2 induced oxidation reactions of protein tyrosine phosphatases. (J Am Soc Mass
Spectrom 2009, 20, 1540–1548) © 2009 Published by Elsevier Inc. on behalf of American Society
for Mass SpectrometryProtein tyrosine phosphatases (PTPs) comprise animportant class of enzymes involved in control ofthe cell cycle and signal transduction by regulat-
ing levels of protein tyrosine phosphorylation in re-
sponse to cellular signals [1–5]. Because of this key
function, PTPs have been implicated in the deve-
lopment of cancer, diabetes, rheumatoid arthritis, and
hypertension [6, 7]. Cysteine residues in PTPs are
highly susceptible to oxidation by reactive oxygen spe-
cies (ROS)/reactive nitrogen species (RNS), because at
neutral pH they exist in thiolate anion (Cys-S) form
due to their low pKa (4.7–5.4) [8]. This property directly
influences and inhibits PTP activity during signaling
processes. Much biochemical evidence suggests that
PTP’s activity is regulated through reversible oxidation
of the catalytic cysteine to cysteine sulfenic acid inter-
mediate by low micromolar concentrations of H2O2 [9].
These active sites can be reactivated by thioredoxin
electron donors [10] and reduction with glutathione
[11]. PTP1B has been studied extensively as it is an
important enzyme in the negative regulation of the
insulin receptor [12, 13], and a therapeutic target in type
II diabetes and obesity [14]. In light of the critical
biologic role of PTP1B and its regulation by cysteine
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doi:10.1016/j.jasms.2009.04.011oxidation, Salmeen et al. used X-ray crystallography
and mass spectrometry to discover a novel “cysteine
sulfenamide” species in the oxidation of PTP1B by
H2O2. This species was identified as a reversible inter-
mediate in the oxidative inhibition of PTP1B, which
may allow reactivation of PTP1B by biological thiols
[15].
Hydroxyl radicals (OH·) are extremely reactive and
can cause irreversible damage to all cellular compo-
nents [16–18]. They can be produced by the reduction of
H2O2 in the presence of iron via the “Fenton reaction”
[19]. Although this reaction is a major source for OH·
formation in cells, these radicals often can be produced
from other cellular oxidants like ONOOH in their
homolytic cleavage reactions [20–22]. Indeed, most of
the amino acid residues of proteins are potential targets
for oxidation by OH· generated by high concentrations
of H2O2 and Fe (II) or by ionizing radiation [23–31].
Increasing evidence suggests that OH· are also involved
in regulating signaling processes of wide variety of
proteins including PTPs [32, 33]. Corroborating the role
of OH· in the control of PTPs, Caselli et al. [34] exam-
ined the inactivation mechanism of low molecular
weight PTPs by H2O2 in vitro and found that addition
of metal chelator to the reaction mixtures caused 17%
and 28% decrease in the inactivation of IF1 and IF2,
respectively. These investigators demonstrated that
OH· partially contributes to this inactivation. In light of
this, we have studied the structures of OH · and H2O2
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minimize the complexity of diverse oxidation products,
we have selected a short synthetic peptide, HCSAGIGRS,
which mimics the active site sequence motif of PTP1B.
Here we report the preparation and characterization by
tandem mass spectrometry of cyclic cysteine sulfin-
amide and cysteine sulfenic acid formed in solution by
reactive oxygen species (OH· and H2O2) mediated oxi-
dation reactions of HCSAGIGRS. These novel oxidative
species of the catalytic cysteine of PTP1B have been
proposed as intermediate steps towards irreversible
inactivation of PTB1B [35], but to the best of our
knowledge never before directly observed in solution.
Experimental
The synthetic peptide HCSAGIGRS was purchased
from GenScript Corp., Scotch Plains, NJ, USA. This
peptide was oxidized using Fenton reagents (Fe2/
H2O2) as reported previously [36]. Briefly, 1 mM pep-
tide solution was incubated at room temperature in the
presence of 0.5 mM FeSO4 and 0.2 mM H2O2 for 30
min. The reaction was terminated by adding aliquots of
methionine solution until its concentration reached 1
mM. Similar conditions were used for the oxidation of
HCSAGIGRS by H2O2 except that the concentration of
H2O2 was 100 M. In direct infusion MS and MS/MS
experiments on a Q TOF Micro instrument (Micromass,
Manchester, United Kingdom), 50% acetonitrile in 0.1%
formic acid was used as the carrier and electrospray
solvent with a flow rate of 500 nL/min. A 1-L aliquot
of 2-M sample solution was injected via a divert valve
in each run under the following source conditions:
spray voltage 1500 to 1800 V, cone voltage 40 V, and
source temperature 80 °C. Argon was used as a collision
gas for all MS/MS experiments. The low mass and high
mass resolution of the quadrupole mass filter before the
TOF analyzer were adjusted for transmission of precur-
sor ions through a mass window of only 1.0 Da. Each
spectrumwas obtained by averaging25 scans, and the
scan time was 1 s/scan. The Q-TOF Micro instrument
was calibrated with [Glu1]-fibrinopeptide B, and the
data in both MS and MS/MS modes were acquired at
5000 resolution. Additional direct infusion tandem
mass spectrometry (MS2 and MS3) experiments were
carried out on an LCQ-Deca XP (Thermo Finnigan, San
Jose, CA, USA) equipped with a nano-ESI source (Jamie
Hill Instrument Services, Arlington, MA, USA). The
carrier solution was 50% acetonitrile in 0.1% formic acid
with a flow rate of 300–500 nL/min. The oxidation
reaction mixture was diluted 5-fold in carrier solution,
and infused directly into the mass spectrometer with
spray voltage of 2.5 kV and temperature for the heated
capillary of 150 °C. The mass width for precursor ion
selection in MS/MS was 1 Da, and the normalized
collision energy was optimized (18%–25%) so that the
precursor ions were clearly present but not the most
abundant ions in the product-ion spectra. Each spec-trum was obtained by averaging 50 scans, and the
time for each scan was 0.1 s.
Data-dependent nanoLC-MS/MS experiments were
carried out using a Waters nanoAcquity UPLC and a
Waters Q-TOF Premier mass spectrometer (Milford,
MA, USA). The analytical column was a Waters Sym-
metry C18, 100 m i.d.  15 cm, with 3.5 m particles.
Mobile phase A was 2% acetonitrile/0.1% formic acid,
while mobile phase B was 90% acetonitrile/0.1% formic
acid in water. The gradient was 5%–90% B over 45 min
at a flow rate of 200 nL/min. Automatic switching
between MS and MS/MS modes was controlled by
MassLynx 4.0 (Micromass), dependent on both signal
intensity and charge states from MS to MS/MS, and on
either signal intensity or time from MS/MS to MS.
Results and Discussion
The peptide HCSAGIGIRS was incubated with Fenton
reagent to form cysteine oxidation products as de-
scribed in the Experimental section, and infused di-
rectly into the Q-TOF Micro instrument for mass spec-
trometry analysis. The partial mass spectrum of the
above reaction mixture is shown in Figure 1a. This
spectrum exhibits singly charged ions at m/z 901.4,
903.4, 919.4 and 935.4, which corresponds to the 14,
16, 32, and 48 Da modifications of HCSAGIGRS (m/z
887.4), respectively. The latter three products at m/z
903.4, 919.4, and 935.4 were characterized as cysteine
sulfenic acid (Figure 1b), cysteine sulfinic acid (Figure
1c), and cysteine sulfonic acid (Figure 1d) products
based on the characteristic fragment ions formed in
their MS/MS spectra. We observed similar MS/MS
spectra for the doubly charged ions of the oxidation
products (data not shown).
Characterization of Cysteine Sulfinamide
(HC[S(O)N]SAGIGRS)
The MS/MS spectra of singly (m/z 901.3) and doubly
(m/z 451.2) charged ions of a product formed in the
oxidation reaction of HCSAGIGRS by Fenton reagents
are shown in Figure 2b and Figure 3b, respectively.
Compared with the MS/MS spectrum of unmodified
peptide HCSAGIGRS in Figure 2a, a mass shift of 14 Da
can be seen in the MS/MS spectrum in Figure 2b for
several b ions [b4 (m/z 413.1), b5 (m/z 470.1), b6 (m/z
583.2), b8 H2O (m/z 814.3)] as well as for three a ions,
[a4 (m/z 385), a5 (m/z 442.2), and a6 (m/z 555.2)]. The
formation of a y6 (m/z 560.3) ion rules out modification
of the AGIGRS fragment. The characteristic ion at m/z
853 due to direct loss of a neutral SO from M  H ions
of m/z 901 and an ion at m/z 207 (b2-SO) localize the site
of modification to the cysteine residue. The MS/MS
spectrum of the doubly charged ion (m/z 451.2) in
Figure 3b displayed an additional characteristic y8 ion
atm/z 764, along with y3 (m/z 319), y5 (m/z 489.2), y6 (m/z
560.3), and b2-SO (m/z 207.1) ions, revealing that cys-
1542 SHETTY AND NEUBERT J Am Soc Mass Spectrom 2009, 20, 1540–1548teine is modified by 14 Da. Thus, the above results
suggest that an intramolecular covalent bond is formed
between the oxidized cysteine residue and the nitrogen
of serine, giving rise to a cysteine sulfinamide product.
The structure of this product and its key fragmentation
pathways are depicted in Scheme 1. Although the
formation of the y7 ion (m/z 647) in MS/MS spectra of
both singly and doubly charged sulfinamide precursor
ions (Figures 2b and 3b) would require complex rear-
rangement reactions in the gas phase, such rearrange-
ments under CID conditions were previously repor-
ted for peptides with sequences PFKCG [37] and
PRCGVPDVA [38]. For example, a prominent gas-
phase rearrangement ion (m/z 373, b3) was observed in
the MS/MS spectra of cyclic cysteine sulfonamide,
cysteine sulfinamide, and cysteine sulfenamide prod-
Figure 1. (a) Q-TOF partial mass spectrum of
reaction of HCSAGIGRS peptide with Fenton
(b) HC(SOH)SAGIGRS (m/z 903.4); (c) HC(SO2H)S
935.4).ucts formed in the oxidation of PFKCG by HOCl [37].With these precedents in mind, we believe the y7 ion
(m/z 647) in MS/MS spectra of both singly and doubly
charged precursor ions (Figures 2b and 3b) may be
formed by a similarly complex gas-phase rearrange-
ment reaction. We do not believe these spectra provide
evidence for a cysteine sulfine because we do not
observe the predicted ions of m/z 839.4 (Figure 2b) or
m/z 420.4 (Figure 3b) caused by the neutral loss of a
stable thio-ketene (CH2SO) from a cysteine sulfine.
Recently, Gates et al. demonstrated, by using a small
organic molecule model of the PTP1B active site, that
the sulfenic acid residue possesses sufficient electrophi-
licity to drive a cyclization reaction with a neighboring
amide group, which leads to the formation of a
3-isothiazolidinone analog [39]. In this study, there was
no evidence for the formation of cysteine sulfine from
H) ions of products formed in the oxidation
nt. Q-TOF MS/MS spectra of (M  H) ions
RS (m/z 919.4); and (d)HC(SO3H)SAGIGRS (m/z(M 
reage
AGIGthe sulfenic acid intermediate. We also do not believe
1543J Am Soc Mass Spectrom 2009, 20, 1540–1548 CYSTEINE OXIDATION PRODUCTS OF PTPSour data can be explained by oxidation of histidine
because the formation of an abundant histidine immo-
nium ion (Figures 2b and 3b) at m/z 110 and a shift of y8
ion from m/z 750 (Figure 3a) to m/z 764 (Figure 3b)
strongly suggest that histidine is not modified. When
we infused the unmodified peptide (m/z 887.4) solution
directly in to the MS, we found no oxidation product
formed atm/z 901, suggesting oxidation did not occur in
Figure 2. Q-TOF MS/MS spectra of (M
(b) HC[S(O)N]SAGIGRS (m/z 901.4).
Figure 3. Q-TOF MS/MS spectra of (M  2H)
cysteine sulfinamide HC[S(O)N]SAGIGRS (m/z
asterisk, are most likely derived from the isobar
in-source loss of water from HC(SO2H)SAGIGRS.the electrospray source of the mass spectrometer (data
not shown).
Interestingly, the MS/MS spectrum shown in Figure
3b is very similar to that of the doubly charged Q-TOF
MS/MS spectrum of HC(SO2H)SAGIGRS (m/z 460.2,
2) (Figure 4a) except for the y8 fragment ion at m/z 764
and differences in the relative intensities of all other
fragment ions. The formation of ions at m/z 273 and
) ions of (a) HCSAGIGRS (m/z 887.4) and
s of (a) HCSAGIGRS (m/z 444.2) and (b) cyclic
). Ions at m/z 273.0 and 418.1, indicated with an
ntaminant of m/z 451.2 (2) ions formed by the H2 ion
451.1
ic co
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possibility of the presence of isobaric impurities at the
m/z 451.2 precursor ions as they were found to be
present in Figure 4a, although at low abundance. More-
over, an intense peak at m/z 451.2 (2) was most likely
due to the loss of water in the ion trap MS/MS analysis
of HC(SO2H)SAGIGRS, as shown in Figure 4b. These
observations led us to carefully investigate the purity as
Scheme 1. Fragmentation pathways of doubly charged cysteine
sulfinamide HC[S(O)N]SAGIGRS (2) ions.
Figure 4. MS/MS spectra of doubly charged ion
(a) Q-TOF and (b) ion trap instruments.well as the mechanism of the formation of cysteine
sulfinamide m/z 451.2 (2) ions. To do this, we used an
ion trap to perform MS2 and MS3 experiments on the
m/z 451.2 (2) parent ions formed in the oxidation
reaction of HCSAGIGRS and on 451.2 (2) product ions
formed by the water loss during the MS/MS analysis of
HC(SO2H)SAGIGRS). These spectra are shown in Fig-
ure 5. Differences can be seen between the MS/MS
spectrum (Figure 5a) and the MS/MS/MS spectrum
(Figure 5b). For example, the spectrum in Figure 5b
displayed a base peak at m/z 418 (2) most likely due to
a facile loss of water in MS/MS, followed by the neutral
loss of H2SO2 in MS/MS/MS. Another ion atm/z 273 (b2
ion of HC(SO2H)SAGIGRS), which is formed by the
cleavage at the C-terminal side of modified cysteine, is
absent in Figure 5a. Likewise, the spectrum in Figure 5a
contains a base peak at m/z 442 (H2O), a series of
abundant y ions and a b6 ion that are of very low in
intensity or absent in Figure 5b. The y8 ion, which is
more intense in Figure 5a, is especially informative.
This suggest that the m/z 451.2 (2) ions formed by the
loss of water from HC(SO2H)SAGIGRS possess a dif-
ferent structure than the cysteine sulfinamide. Thus,
based on the above experimental results, it seems most
likely that the majority of the ions at m/z 451.2 (2)
belong to the cysteine sulfinamide product formed
directly in the oxidation reaction. However, a minor
contribution via the loss of water (most likely in-source)
from HC(SO2H)SAGIGRS under our MS experimental
conditions cannot be ruled out. In sum, we conclude
that our data are consistent with multiple mechanisms
for the formation of the cysteine sulfinamide product.
HC(SO H)SAGIGRS (m/z 460.2,2) obtained bys of 2
1545J Am Soc Mass Spectrom 2009, 20, 1540–1548 CYSTEINE OXIDATION PRODUCTS OF PTPSWe have also carried out data-dependent nano LC-
MS/MS experiments to separate and characterize the
cyclic cysteine sulfinamide oxidation product. We ob-
tained the SICs for m/z 451.2 ions as well as m/z 460.2
ions (Figure 6) from an LC-MS/MS experiment. We
found one MS/MS spectrum for a precursor ion of m/z
451.2 (Figure 6d) at 14 min RT (Figure 6c) when the
cysteine sulfinic acid oxidation product (m/z 460.2)
eluted (Figure 6b). We found another MS/MS spectrum
for m/z 451.2 (Figure 6e) acquired at 31 min (Figure 6c).
These two MS/MS spectra were recorded with similar
S/N ratios, but the spectra differ in several respects.
The y8 ion at m/z 764 is completely absent from the
MS/MS spectrum obtained at 14 min (Figure 6d),
whereas it is clearly present in the MS/MS spectrum
that is obtained at 31 min (Figure 6e). Also, the MS/MS
spectrum at 31 min contains a more prominent series
of y ions compared witih the MS/MS spectrum at 14
min. The formation of a low intensity m/z 418 ion in
Figure 6e may be due to poor HPLC separation and
contamination by the high concentration of the cys-
teine sulfinic acid oxidation product. These results
suggest that the cysteine sulfinamide product (elut-
ing predominantly at 31 min) is formed directly from
the oxidation of HCSAGIGRS peptide, and is not a
water loss product of cysteine sulfinic acid (eluting
predominantly at 14 min).
These results are complementary to a recent study of
PTP1B by Salmeen et al. who discovered a novel
intermediate “cysteine sulfenamide” in the hydrogen
Figure 5. Ion trap spectra: (a) MS/MS spectrum
(b) MS/MS/MS spectrum of m/z 451.2 (2) io
MS/MS of m/z 460.2 (2).peroxide mediated inactivation of PTP1B [15]. Theyproposed a mechanism for cysteine sulfenamide forma-
tion in which active site cysteine thiol undergoes oxi-
dation to give sulfenic acid, followed by cyclization of
the amide nitrogen onto the oxidized sulfur residue.
These authors reinvestigated cysteine sulfenamide for-
mation in PTP1B and found that the “sulfenamide
bond” is stable for more than 5 h [34]. Nevertheless, in
the current study, the cysteine sulfinamide structure
that we characterized has an additional oxygen atom on
the sulfur that could be formed when cysteine sulfen-
amide undergoes further oxidation. Salmeen et al. pro-
posed an identical cysteine sulfinamide intermediate in
the irreversible H2O2 oxidation of the cysteine thiol to
cysteine sulfinic acid [35]. Based on these previously
reported results and our current experimental findings,
we propose a mechanism for the formation of a cysteine
sulfinamide product starting with an OH· attack on the
SH group of cysteine in the HCSAGIGRS peptide as
illustrated in Scheme 2.
To investigate the formation of cysteine sulfinamide
via H2O2 oxidation of the HCSAGIGRS peptide, we
incubated the peptide with 100 M H2O2 at RT for 30
min while minimizing contamination by metal ions. We
obtained a Q-TOF LC-MS/MS spectrum virtually iden-
tical to that of the cysteine sulfinamide ion at m/z 451.2
(2) formed in the oxidation reaction of HCSAGIGRS
by Fenton reagent. These results suggest that cyclic
cysteine sulfinamide may be a key intermediate in the
irreversible oxidation by both OH· and H2O2 oxidants
m/z 451.2 (2) ions of HC[S(O)N]SAGIGRS and
f [HC(SO2H)SAGIGRS(-H2O)] produced in theof
ns oof the active site cysteine in PTP1B.
red a
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[HC(SOH)SAGIGRS]
To investigate the formation of a potential cysteine
sulfenic acid intermediate, the Fenton reagent oxidation
reaction mixture was infused directly into a Q-TOF
Micro mass spectrometer immediately after addition of
the reagent to HCSAGIGRS peptide. A clear peak at m/z
903.4 can be seen in the mass spectrum (Figure 1a). The
MS/MS spectrum of this m/z 903.4 ion (Figure 1b)
shows a series of y ions, including y3 and y5-y7, which
confirmed the amino acid sequence SAGIGRS. Histi-
dine modification is unlikely because of the formation
of its abundant immonium ion at m/z 110. These data
indirectly suggest that cysteine is modified. In addition,
the ion at m/z 853.4 indicating the loss of neutral H2SO
from the parent ion confirmed that cysteine is modified
to cysteine sulfenic acid [HC(SOH)SAGIGRS]. A low
abundance ion at m/z 853 ion formed by the loss of
neutral H2S is also present in Figure 2a. A similar H2SO
Figure 6. (a) LC-MS chromatogram of produc
peptide with Fenton reagent and selected ion chr
LC-MS/MS spectra of m/z 451.2 (2) ions acquiloss was observed in the MS/MS spectrum of anotherpeptide, PRC(SOH)GVPDVA (m/z 929.4), which we
recently characterized as a stable sulfenic acid oxidation
product [38]. Furthermore, modification of cysteine to
cysteine sulfenic acid induced the preferred formation
of abundant y ions over b ions as in the MS/MS spectra
of cysteine sulfinic acid [HC(SO2H)SAGIGRS] and cys-
teine sulfonic acid [HC(SO3H)SAGIGRS] (Figure 1c and
d). Figure 1b–d show that the y7 ion formed by the facile
cleavage at C-terminal side of the modified cysteine resi-
due is relatively intense while it is almost absent in the
MS/MS spectrum of unmodified HCSAGIGRS (Figure
2a). Thus, cysteine sulfenic acid undergoes very similar
fragmentation as cysteine sulfinic acid and cysteine sul-
fonic acid in our MS/MS experiments. It has been pro-
posed that cysteine sulfenic acids in proteins are stabilized
by hydrogen bonding with amino or carbonyl groups [38,
40]. We suggest similar hydrogen bonding interactions to
stabilize cysteine sulfenic acid in the PTB1B active site
sequence HC(SOH)SAGIGRS, perhaps due to strong hy-
med in the oxidation reaction of HCSAGIGRS
ograms (SIC) of (b) 460.2 ions and (c) 451.2 ions.
t RTs (d) at 14 min and (e) at 31 min.ts for
omatdrogen bonding between the SOH group and the imida-
id.
1547J Am Soc Mass Spectrom 2009, 20, 1540–1548 CYSTEINE OXIDATION PRODUCTS OF PTPSzole ring of histidine. These results are consistent with
evidence for the presence of cysteine sulfenic acid in
PTP1B in response to H2O2 oxidation obtained by Barrett
et al. [41] and Denu et al. [42], using the trapping reagent
NBD-Cl. While there are many reports describing the
significance of cysteine sulfenic acid intermediates in
redox signaling in biologically important proteins (re-
viewed in [43], our results do not directly demonstrate
that cysteine sulfenic acid is an intermediate for the
formation of cysteine sulfinamide in PTP1B.
Conclusions
We used mass spectrometry to characterize several
oxidation products of a synthetic peptide containing the
PTP1B active site sequence motif, HCSAGIGRS. We
found a previously unknown oxidation product, cys-
teine sulfinamide, which may be formed in the irrevers-
ible oxidation of catalytic cysteine in PTP1B. The direct
identification of cysteine sulfenic acid in our experi-
ments suggests that it might be a key intermediate in
the formation of the cysteine sulfinamide product. Our
findings suggest plausible OH. and H2O2 mediated
oxidation products of PTP1B that may be formed when
the Fe-catalyzed Fenton reaction prevails in cellular
responses to high oxidative stress situations, increase in
H2O2 levels, and/or exposure to high-energy irradia-
tion such as x-rays,  rays, or UV radiation.
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